Christa

Jim Carroll delivered the keynote address at the Chronic Disease Fund’s 5th Annual Partnership Summit in Dallas, Texas in September 2012, speaking to healthcare professionals, pharmaceutical executives, and patient advocacy leaders united by a shared commitment to ensuring patient access to critical medications. The Chronic Disease Fund (now known as Good Days) is one of the largest independent co-pay assistance foundations in the United States, and its annual summit brings together its network of pharmaceutical partners, patient organizations, and healthcare system stakeholders. Carroll’s keynote, “Healthcare 2020: The Transformative Trends That Will REALLY Define Our Future,” challenged the audience to look beyond the immediate pressures of the Affordable Care Act’s implementation and engage with the deeper technological transformation of healthcare — from genomic medicine and connected health devices to artificial intelligence tools that were beginning to outperform human diagnosis in specific disease categories. The talk reinforced Carroll’s ongoing argument that the future of medicine was fundamentally about scientific acceleration, not political debate.

Jim Carroll delivered a keynote address to senior leadership at DuPont in 2012, exploring the innovation imperatives facing one of the world’s oldest and most storied science-based companies in a period of rapid industry disruption. DuPont, with nearly 210 years of history in chemistry, materials science, agriculture, and industrial biotechnology, represented exactly the kind of deep-capability organization that Carroll challenged to marry its scientific heritage with the speed and boldness of a startup. Carroll’s work with large industrial and science companies during this period consistently returned to the theme of “innovation and the 10 great words” — challenging leaders to articulate a clear, bold innovation mandate that could cascade through a complex global organization. The session reflected Carroll’s ongoing engagement with the manufacturing and materials science sector during a period when breakthrough science in genomics, nanotechnology, and advanced materials was beginning to reshape the competitive landscape of industrial chemistry.